INOFEA AG ANNOUNCES CLOSING OF ITS SERIES A+ ROUND WELL ABOVE TARGET.
This week, INOFEA successfully closed its financing round with contributions from returning as well as new private investors.
CEO Dr. Yves Dudal states: ”I am thrilled by the great support from our investors and the acceptance of our business model. We will use these funds to progress into a product based company by continuously growing the sales of empowered enzymes, and also explore the benefits of the platform for therapeutic enzymes in high medical need areas”.
The company was founded in 2014 in Basel as a spin-out from the School of Life Sciences, University of Applied Sciences and Arts, Northwestern Switzerland (FHNW).
INOFEA owns a highly innovative nanotechnology platform to shield sensitive enzymes and has positively demonstrated substantial benefits to customers in a number of biopharma-related applications.